Reims Cedex

• API-AHAI - Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a P … Recruiting
  2024-513191-17-00 4 2022-02-03 autoimmune hemolytic anemia
• Study evaluating the interest of imatinib treatment maintenance or interruption after at least 10 years of treatment in patients with locall … Recruiting
  2024-512631-77-00 4 2021-12-20 locally advanced or metastatic Gastrointestinal Stromal Tumors
• A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Recruiting
  2022-501050-11-01 10 2020-07-13 Acute Lymphoblastic Leukaemia
• Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for … Recruiting
  2024-511904-18-00 10 2020-07-08 Pancreatic adenocarcinoma (PAC)
• Non inferiority study of preoperative chemotherapy without pelvic irradiation for rectal cancer Recruiting
  2024-510580-28-00 5 2019-06-05 Middle or low locally advanced resectable rectal carcinoma
• TRAUMADORNASE A Prospective, Randomized Multicenter, Double Blind Clinical Trial Comparing Inhaled Dornase Alfa and Its Placebo to Reduce th … Recruiting
  2024-512034-14-00 5 2019-03-04 severe trauma
• Avoid Anticoagulation After IntraCerebral Haemorrhage Recruiting
  2024-514094-22-00 5 2019-01-18 Intrecerebral Haemorrhage
• Paediatric Hepatic International Tumour Trial Recruiting
  2024-516110-38-00 5 2018-03-06 Hepatoblastoma and Hepatocellular Carcinoma
• CLAZI : CLArithromycin versus AZIthromycin in the treatment of Mycobacterium avium complex pulmonary infections: A randomized prospective co … Recruiting
  2024-518578-15-00 5 2018-02-05 Is to demonstrate a non inferior efficacy of azithromycin and so the p
• Efficacy of adjuvant Imatinib in patients with intermediate-risk gastrointestinal stromal tumor with a high-risk Genomic Grade Index Recruiting
  2024-515432-71-00 5 2016-09-13 gastrointestinal stromal tumor
• GRAALL2014 Recruiting
  2024-516103-16-00 4 2015-12-04 Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
• SIOP Ependymoma II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependym … Recruiting
  2024-512222-28-00 10 2015-06-02 Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
• Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication: BIOMEDE 2.0 Recruiting
  2023-506027-29-00 5 2014-10-01 Children, adolescents and adults with newly diagnosed diffuse intrinsi
• PEHRICCA : PErioperative CISGEM plus RILVEGOSTOMIG in High-Risk resectable Intrahepatic CholangioCarcinoma Ended recruitment
  2025-521302-17-00 10 2026-05-26 Hihg risk of cholangiocarcinoma intra hépatic resectable
• Phase 3 trial aimed at improving the overall survival of AML in adults aged 18 to 60 by comparing high-dose idarubicin with daunorubicin at … Ended recruitment
  2024-516873-57-00 10 2026-01-13 Acute myeloid leukemia in adults aged 18 to 60
• A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 … Ended recruitment
  2024-512914-16-00 5 2025-09-12 Relapsing-remitting Multiple Sclerosis
• A trial to learn how safe AZD8630 is and how well it works in adults with uncontrolled asthma. Ended recruitment
  2024-514228-18-00 4 2025-01-16 Asthma in adults who remain uncontrolled despite medium to high dose I
• A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheu … Ended recruitment
  2023-508077-85-00 5 2024-11-19 Polymyalgia Rheumatica
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended recruitment
  2023-508636-61-00 5 2024-10-24 Crohn’s Disease
• JAK1 inhibitor treatment of inflammatory liver adenomas Ended recruitment
  2023-505278-13-00 4 2024-10-01 -women with an inflammatory HCA proven at histology and with at least
• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Ended recruitment
  2022-502781-24-01 5 2024-06-05 ASCVD - Atherosclerotic Cardiovascular Disease
• A study to investigate long-term safety and tolerability of itepekimab in participants with COPD Ended recruitment
  2023-508085-15-00 5 2024-05-15 Chronic Obstructive Pulmonary Disease
• Study to evaluate the efficacy and safety of BGB-11417 in participants with Waldenström’s Macroglobulinemia Ended recruitment
  2023-503235-18-00 4 2024-01-31 previously untreated WM
• Determine effectiveness of Anifrolumab In Systemic sclerosis Ended recruitment
  2023-505976-31-00 5 2023-11-24 Systemic Sclerosis (SSc) presenting with Limited or Diffuse Cutaneous

Showing 121–144 of 216 trials